Figure 1.

Illustration of upfront LAT approach for a metachronous OM-NSCLC disease with 3 disease sites (1 each in left lung, right lung, and liver) using SABR as LAT modality. All known disease sites presumed inactive after LAT. Systemic therapy commonly started soon after LAT completion, prior to objective tumor response (i.e., shrinkage). Reduction in tumor circle size represents partial response, while disappearance represents complete response. LAT, local ablative therapies; OM, oligometastatic; NSCLC, non-small cell lung cancer; SABR, stereotactic ablative radiotherapy.